Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Chemical Biology and Drug Design

• Publication date

  2015-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/cbdd.12480PMID 25407396
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

  2017influential reference
• Mutant p53 targeting by the low molecular weight compound STIMA‐1

  2017influential reference
• Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.

  2014cited by this paper
• Targeting MDM2-p53 interaction for cancer therapy: are we there yet?

  2014cited by this paper
• p53 mutations in cancer

  2013cited by this paper
• Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

  2013influential reference
• Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

  2012cited by this paper
• Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.

  2012cited by this paper
• Mutant p53: one name, many proteins.

  2012cited by this paper
• Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies

  2011cited by this paper
• Effects of Temperature on the p53-DNA Binding Interactions and Their Dynamical Behavior: Comparing the Wild Type to the R248Q Mutant

  2011cited by this paper
• p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.

  2011cited by this paper
• A Medicinal Chemist’s Guide to Molecular Interactions

  2010cited by this paper
• Automated Docking of Flexible Ligands to Flexible Receptors

  2010cited by this paper
• Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.

  2010cited by this paper
• The first 30 years of p53: growing ever more complex

  2009cited by this paper
• PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.

  2009cited by this paper
• AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

  2009cited by this paper
• Mutant p53 targeting by the low molecular weight compound STIMA‐1

  2008cited by this paper
• Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

  2008cited by this paper
• Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

  2008influential reference
• Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms.

  2007influential reference
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome

  2007cited by this paper
• TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

  2007cited by this paper
• Ex vivo expansion, adipogenesis and neurogenesis of cryopreserved human bone marrow mesenchymal stem cells

  2007cited by this paper
• PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations

  2007influential reference
• Comparison of multiple Amber force fields and development of improved protein backbone parameters

  2006cited by this paper
• Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

  2006cited by this paper
• The Consensus Coding Sequences of Human Breast and Colorectal Cancers

  2006cited by this paper
• Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

  2005cited by this paper
• Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs*

  2005cited by this paper
• Scalable molecular dynamics with NAMD

  2005cited by this paper
• Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis.

  2004influential reference
• CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73*

  2004cited by this paper
• Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

  2004cited by this paper
• Rescue of mutant p53 transcription function by ellipticine

  2003cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002influential reference
• The IARC TP53 database: New online mutation analysis and recommendations to users

  2002cited by this paper
• Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

  2002cited by this paper
• Restoration of wild‐type conformation and activity of a temperature‐sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE‐1

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• The MDM2 gene amplification database.

  1998cited by this paper
• IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools

  1998cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling

  1997cited by this paper
• MDMX: a novel p53‐binding protein with some functional properties of MDM2.

  1996cited by this paper
• Overview Oncologic, Endocrine & Metabolic: Oncologic, Endocrine & Metabolic :Ellipticine and related anticancer agents

  1996cited by this paper
• Inhibition of p53 Protein Phosphorylation by 9‐Hydroxyellipticine: A Possible Anticancer Mechanism

  1995cited by this paper
• Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

  1994cited by this paper
• ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES

  1980cited by this paper
• A Cluster Separation Measure

  1979influential reference
• Tables of Interatomic Distances and Configuration in Molecules and Ions.

  1959cited by this paper

• Investigation of Chemical Constituents, Anti‐oxidant, Anti‐inflammatory, and Anti‐cancer Effects of the Essential Oil Isolated From Nosema cochinchinensis Leaves

  2025cites this paper
• Lichen Depsidones with Biological Interest

  2021cites this paper
• The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

  2018cites this paper
• Virtual screening using covalent docking to find activators for G245S mutant p53

  2018cites this paper
• Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA

  2017cites this paper